<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/DCEC74AE-6E7C-40FC-BFCA-C52990BCEE56"><gtr:id>DCEC74AE-6E7C-40FC-BFCA-C52990BCEE56</gtr:id><gtr:name>School of Clinical Medicine</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Institute of Neurology</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/82200E1A-04DA-42F5-80F3-B0FF026643BD"><gtr:id>82200E1A-04DA-42F5-80F3-B0FF026643BD</gtr:id><gtr:name>University of Copenhagen</gtr:name><gtr:address><gtr:line1>Norregade 10</gtr:line1><gtr:line2>Postboks 2177</gtr:line2><gtr:line4>Copenhagen K</gtr:line4><gtr:line5>DK-1017</gtr:line5><gtr:region>Outside UK</gtr:region><gtr:country>Denmark</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/7BC6FCF2-358C-45C5-A5A7-E859DD754711"><gtr:id>7BC6FCF2-358C-45C5-A5A7-E859DD754711</gtr:id><gtr:name>Lund University</gtr:name><gtr:address><gtr:line1>Box 117</gtr:line1><gtr:line2>S-221 00</gtr:line2><gtr:line4>Lund</gtr:line4><gtr:postCode>S-221 00</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/DCEC74AE-6E7C-40FC-BFCA-C52990BCEE56"><gtr:id>DCEC74AE-6E7C-40FC-BFCA-C52990BCEE56</gtr:id><gtr:name>School of Clinical Medicine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/84F33A16-13EA-48F9-886F-851E3DD949EA"><gtr:id>84F33A16-13EA-48F9-886F-851E3DD949EA</gtr:id><gtr:firstName>Adrian</gtr:firstName><gtr:surname>Isaacs</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=MR%2FJ004022%2F1"><gtr:id>D9E5CCED-A69C-4DF2-8562-DCB4EB6AECE1</gtr:id><gtr:title>Investigation of the mechanism of CHMP2B-induced neurodegeneration using a novel transgenic mouse model</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>MR/J004022/1</gtr:grantReference><gtr:abstractText>The neurodegenerative diseases, which include Alzheimer's disease, Parkinson's disease, Huntington's disease, motor neuron disease and prion diseases cause huge social and economic burden. This burden is set to increase dramatically as the population ages. Currently no therapies are available for these diseases, implying an urgent need to better understand their causes and develop therapies. We have identified a new gene, termed CHMP2B, that causes an inherited form of dementia. We have shown that CHMP2B affects the ability of cells to break down proteins, which is a problem that has been identified in many other neurodegenerative diseases. We therefore plan to further investigate how CHMP2B affects brain cells as this should give insight into pathways that could be targeted therapeutically in many neurodegenerative diseases. However, a major challenge for developing therapies is understanding why brain cells are specifically affected, so that directed therapies without side effects can be developed. In order to understand how CHMP2B specifically affects brain cells, we have generated mice that model dementia caused by CHMP2B. These mice are a very powerful model as they mimic the processes occurring in human CHMP2B dementia brains. They will therefore allow us to specifically examine brain cells at very early stages of the disease in order to identify why they are particularly vulnerable to dysfunction and death. Identification of these pathways should give insight into brain cell vulnerability in other neurodegenerative diseases and could identify new avenues for treatments.</gtr:abstractText><gtr:technicalSummary>The neurodegenerative diseases cause a devastating social and economic burden which will increase further as the population ages. No disease-modifying therapies are currently available, implying an urgent need to better understand neurodegenerative disease mechanisms in order to provide the foundation for therapeutic interventions. Mutations in the CHMP2B gene cause frontotemporal dementia, and affect two key cellular degradative pathways that converge on the lysosome: the endosome-lysosome pathway and autophagy. Both pathways have been implicated in a range of neurodegenerative diseases, suggesting that defining the mechanisms of CHMP2B-induced neurodegeneration will have broad impact for our understanding of neurodegenerative disease pathogenesis. However, how impairments in these central degradative pathways lead to selective neuronal dysfunction is unknown. This is a fundamental question as gaining insight into neuronal vulnerability is a key step for developing mechanism-based therapeutics. We have developed the first mouse model of CHMP2B-induced neurodegeneration, which recapitulates key aspects of human pathology. We will analyse endosomal and autophagic trafficking in primary neuronal cultures from these novel mice, in order to gain insight into the specific functions of these pathways that are required for neuronal survival. We will couple this analysis with state-of-the-art mass spectrometry to determine the specific proteins that accumulate due to impairments in these pathways. These insights should identify novel mechanisms that can be targeted therapeutically in a wide range of neurodegenerative diseases.</gtr:technicalSummary><gtr:potentialImpactText>The aim of this proposal is to generate new knowledge about the mechanisms that lead to neurodegenerative diseases. 

This knowledge will benefit the biotech/pharmaceutical industry by providing new leads for the development of therapeutics for neurodegenerative diseases. They may also benefit from our training of highly skilled researchers with the opportunity to transfer their skills to the biotech/pharmaceutical or related industries.

Dementia patients will ultimately benefit from the development of drugs that can slow or halt their disease; this would directly contribute to improving the health and well-being of society. The development and commercialisation of a dementia therapy would also lead to huge economic benefit.</gtr:potentialImpactText><gtr:fund><gtr:end>2015-10-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-07-16</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>483597</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Institute of Neurology</gtr:department><gtr:description>FReJA consortium</gtr:description><gtr:id>A0302EAA-D138-40DD-B543-FBEF3212BFDD</gtr:id><gtr:impact>9 publications (PMIDs): 20223751, 19202337, 19150504, 18484988, 17917582, 22422914, 22786763, 23142962, 26358247. The FReJA consortium also engages in public engagement providing feedback to patients with CHMP2B mutations at regular meetings.</gtr:impact><gtr:partnerContribution>Provision of samples and expertise</gtr:partnerContribution><gtr:piContribution>Our group leads this consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>School of Clinical Medicine</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Neurology</gtr:department><gtr:description>FReJA consortium</gtr:description><gtr:id>250E9065-C8A9-4B7D-AA18-025C4A025430</gtr:id><gtr:impact>9 publications (PMIDs): 20223751, 19202337, 19150504, 18484988, 17917582, 22422914, 22786763, 23142962, 26358247. The FReJA consortium also engages in public engagement providing feedback to patients with CHMP2B mutations at regular meetings.</gtr:impact><gtr:partnerContribution>Provision of samples and expertise</gtr:partnerContribution><gtr:piContribution>Our group leads this consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Lund University</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>FReJA consortium</gtr:description><gtr:id>67D72A97-CE61-4D74-90CD-1F76164F5D46</gtr:id><gtr:impact>9 publications (PMIDs): 20223751, 19202337, 19150504, 18484988, 17917582, 22422914, 22786763, 23142962, 26358247. The FReJA consortium also engages in public engagement providing feedback to patients with CHMP2B mutations at regular meetings.</gtr:impact><gtr:partnerContribution>Provision of samples and expertise</gtr:partnerContribution><gtr:piContribution>Our group leads this consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Copenhagen</gtr:collaboratingOrganisation><gtr:country>Denmark, Kingdom of</gtr:country><gtr:description>FReJA consortium</gtr:description><gtr:id>8F2F5DF3-2EFD-492F-AB3E-8D8178CEC6E6</gtr:id><gtr:impact>9 publications (PMIDs): 20223751, 19202337, 19150504, 18484988, 17917582, 22422914, 22786763, 23142962, 26358247. The FReJA consortium also engages in public engagement providing feedback to patients with CHMP2B mutations at regular meetings.</gtr:impact><gtr:partnerContribution>Provision of samples and expertise</gtr:partnerContribution><gtr:piContribution>Our group leads this consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>UCL Institute of Neurology</gtr:department><gtr:description>FReJA consortium</gtr:description><gtr:id>F16D3650-226D-4207-9035-B452EC47E1C7</gtr:id><gtr:impact>9 publications (PMIDs): 20223751, 19202337, 19150504, 18484988, 17917582, 22422914, 22786763, 23142962, 26358247. The FReJA consortium also engages in public engagement providing feedback to patients with CHMP2B mutations at regular meetings.</gtr:impact><gtr:partnerContribution>Provision of samples and expertise</gtr:partnerContribution><gtr:piContribution>Our group leads this consortium.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Press release (Science paper)</gtr:description><gtr:form>A press release, press conference or response to a media enquiry/interview</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>0B85C021-7434-41DB-AB8B-3B8BB2100FEF</gtr:id><gtr:impact>Our research was reported by 5 news outlets

Media activity about our paper led to an Altmetric score of 91.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Media (as a channel to the public)</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>FTDtalk</gtr:description><gtr:form>Engagement focused website, blog or social media channel</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5B9879EF-A2B8-4ACB-A28C-E20DF6317802</gtr:id><gtr:impact>We developed a website and twitter and facerbook resource called FTDtalk, for patients, carers and the wider public to enable greater understanding of frontotemporal dementia. The website gets 3000-4000 visits per month and positive feedback from users.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Patients, carers and/or patient groups</gtr:primaryAudience><gtr:url>http://www.ftdtalk.org/</gtr:url><gtr:year>2014,2015,2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient Feedback (Denmark)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>7934A126-DC34-43E1-9627-75783679266E</gtr:id><gtr:impact>An update on research findings was provided to approximately 40 family members with inherited dementia. This sparked discussion regarding genetic testing for the condition and volunteering for blood donation.

31 family members donated blood for research.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2010,2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Ada Lovelace Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>740EDC2B-1156-44A2-9060-3EF57AF2FA7B</gtr:id><gtr:impact>Talks and research demonstration led to many thoughtful questions and discussion.

Visit by female GCSE pupils who stated they were more likely to try to get a job in science.</gtr:impact><gtr:partOfOfficialScheme>true</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Web news article (Science paper)</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>64A26C12-C54E-460E-81F2-50FE09703678</gtr:id><gtr:impact>The Motor Neurone Disease Association wrote an article for their website about our paper published in Science, linked to a more detailed blog post. Usage statistics were: the announcement of the website and blog reached 10,300 Facebook users and 1023 twitter feeds; the website news piece had 1010 views; the blog article had 1146 views.

998 Facebook users engaged with the blog and news story: 289 users were talking about the feature; 225 users 'liked' the post; 76 users 'shared' the post to their Facebook friends; 34 people commented on the post (highlighting that it's a great development which they hope can lead to new understandings and treatments in the future).</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2012,2014</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>1899000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Research Grant</gtr:description><gtr:end>2016-04-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>E38A77E7-9FBE-4A65-8752-AAD875B6DBE5</gtr:id><gtr:sector>Academic/University</gtr:sector><gtr:start>2015-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>30891</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>ARUK Pilot Project</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>Alzheimer's Research UK</gtr:fundingOrg><gtr:id>2557F27C-8577-4E7F-8512-2F8C4EE7F460</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2014-12-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We developed a novel RNA fluorescence in situ hybridisation (FISH) assay combined with protein immunofluorescence (IF) to identify and characterise new pathology in frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) caused by C9orf72 mutation (the most common cause of FTD and ALS) . The technique is more sensitive than any previously reported and we are now providing it to the research community.</gtr:description><gtr:id>BC0EBA7B-4B7D-401E-B3FA-9EC93C3A635E</gtr:id><gtr:impact>Publication: Mizielinska S, Lashley T, Norona FE, Clayton EL, Ridler CE, Fratta P, Isaacs AM. C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci. Acta Neuropathol. Epub Oct 2013. PMID:24170096.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>C9orf72 RNA FISH + IF protocol</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We generated novel DNA constructs containing different versions and lengths of the C9orf72 repeat expansion that is a common cause of neurodegeneration.</gtr:description><gtr:id>5E9D6FD3-5ABF-4759-9EB6-D062F1B51E93</gtr:id><gtr:impact>Publication: Mizielinska S, et al C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins. Science. 2014; 345:1192-1194.
Large volume of requests for the DNA constructs from around the world.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>C9orf72 repeat DNA constructs</gtr:title><gtr:type>Model of mechanisms or symptoms - in vitro</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We developed novel Drosophila models of neurodegeneration caused by the C9orf72 repeat expansion, which is a common genetic cause of neurodegeneration.</gtr:description><gtr:id>496A49D3-B0CF-4B77-B450-A6CC1C3D27E2</gtr:id><gtr:impact>Publication: Mizielinska S et al Science. 2014; 345:1192-1194.
A large volume of requests for the Drosophila models from around the world</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>C9orf72 Drosophila models</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type><gtr:yearFirstProvided>2014</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/88EEFCF8-3865-4788-BBD0-20E0EC407A46"><gtr:id>88EEFCF8-3865-4788-BBD0-20E0EC407A46</gtr:id><gtr:title>Regulation of postsynaptic function by the dementia-related ESCRT-III subunit CHMP2B.</gtr:title><gtr:parentPublicationTitle>The Journal of neuroscience : the official journal of the Society for Neuroscience</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/42dd8c8b96ae97d75d1b4e1abfd61280"><gtr:id>42dd8c8b96ae97d75d1b4e1abfd61280</gtr:id><gtr:otherNames>Chassefeyre R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-6474</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/0F29EB25-EA09-4649-920B-DF66AF8B5DD4"><gtr:id>0F29EB25-EA09-4649-920B-DF66AF8B5DD4</gtr:id><gtr:title>Conformation determines the seeding potencies of native and recombinant Tau aggregates.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/17b63d4098cddfd791643c58a7147874"><gtr:id>17b63d4098cddfd791643c58a7147874</gtr:id><gtr:otherNames>Falcon B</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/AFB59A63-D861-4F1D-8F73-86A20A744E7C"><gtr:id>AFB59A63-D861-4F1D-8F73-86A20A744E7C</gtr:id><gtr:title>C9orf72 repeat expansions cause neurodegeneration in Drosophila through arginine-rich proteins.</gtr:title><gtr:parentPublicationTitle>Science (New York, N.Y.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32f0eec9d99a9f9c30f1d78b95480322"><gtr:id>32f0eec9d99a9f9c30f1d78b95480322</gtr:id><gtr:otherNames>Mizielinska S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0036-8075</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/1DEADF0A-B470-4F57-948C-747968B3EA79"><gtr:id>1DEADF0A-B470-4F57-948C-747968B3EA79</gtr:id><gtr:title>RANTing about C9orf72.</gtr:title><gtr:parentPublicationTitle>Neuron</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/b3ab405150e2089e42f3d42e7d67f33a"><gtr:id>b3ab405150e2089e42f3d42e7d67f33a</gtr:id><gtr:otherNames>Lashley T</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0896-6273</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/F9D1C0AE-B40C-4443-86B2-FC922609F19C"><gtr:id>F9D1C0AE-B40C-4443-86B2-FC922609F19C</gtr:id><gtr:title>C9orf72 frontotemporal lobar degeneration is characterised by frequent neuronal sense and antisense RNA foci.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/32f0eec9d99a9f9c30f1d78b95480322"><gtr:id>32f0eec9d99a9f9c30f1d78b95480322</gtr:id><gtr:otherNames>Mizielinska S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B65078ED-9A38-488A-B666-0A58497FC0F8"><gtr:id>B65078ED-9A38-488A-B666-0A58497FC0F8</gtr:id><gtr:title>Early microgliosis precedes neuronal loss and behavioural impairment in mice with a frontotemporal dementia-causing CHMP2B mutation.</gtr:title><gtr:parentPublicationTitle>Human molecular genetics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d371ed1fef27a7d68529eead82f76ad7"><gtr:id>d371ed1fef27a7d68529eead82f76ad7</gtr:id><gtr:otherNames>Clayton EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0964-6906</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/400A4BB2-4A5F-4E14-BB95-A93C71BBC7D5"><gtr:id>400A4BB2-4A5F-4E14-BB95-A93C71BBC7D5</gtr:id><gtr:title>Cognitive impairment in the preclinical stage of dementia in FTD-3 CHMP2B mutation carriers: a longitudinal prospective study.</gtr:title><gtr:parentPublicationTitle>Journal of neurology, neurosurgery, and psychiatry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/50f440bad2db7293a597baaa7cc0d812"><gtr:id>50f440bad2db7293a597baaa7cc0d812</gtr:id><gtr:otherNames>Stokholm J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0022-3050</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/2D6923E3-9810-4B00-B3AE-4C10D73F22DA"><gtr:id>2D6923E3-9810-4B00-B3AE-4C10D73F22DA</gtr:id><gtr:title>Adult polyglucosan body disease with GBE1 haploinsufficiency and concomitant frontotemporal lobar degeneration.</gtr:title><gtr:parentPublicationTitle>Neuropathology and applied neurobiology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/c4cf9de1092a33bca49d6c4f58cb4e5c"><gtr:id>c4cf9de1092a33bca49d6c4f58cb4e5c</gtr:id><gtr:otherNames>Bit-Ivan EN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0305-1846</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/50E1E0A0-FC0F-47C3-8987-952603EA812A"><gtr:id>50E1E0A0-FC0F-47C3-8987-952603EA812A</gtr:id><gtr:title>Frontotemporal dementia caused by CHMP2B mutation is characterised by neuronal lysosomal storage pathology.</gtr:title><gtr:parentPublicationTitle>Acta neuropathologica</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/d371ed1fef27a7d68529eead82f76ad7"><gtr:id>d371ed1fef27a7d68529eead82f76ad7</gtr:id><gtr:otherNames>Clayton EL</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0001-6322</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/J004022/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>041997EB-CFD8-493D-B0F8-DFA35451D0BE</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Neurological</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>